Please assess the completion status of the following clinical trial:

Trial Title: PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~General:~Informed consent signed and dated by study patient and investigator/authorised physician~* Minimum age of 18 years~* Ability to understand the nature and requirements of the study~Study-specific:~* Heart failure patients with preserved, mid-range or reduced ejection fraction (confirmed according to the current definitions of heart failure with preserved (HFpEF), mid-range (HFmrEF) and reduced ejection fraction (HFrEF) requiring echocardiographic assessment within the prior 12 months) who are admitted to the hospital due to signs/symptoms of congestion (left- or right sided)~* On regularly scheduled oral loop diuretics prior to admission~* Patients who have received IV loop diuretics for decongestion within 24 hours after hospital admission and prior to screening. The dosages are administered according to clinical judgment.\*\* (\*\*This inclusion criterion was changed with CIP amendment; in former version 3.0 it read After pre-screening and prior to final screening for eligibility, patients who have received two boluses of IV loop diuretics (Dose according to the Furosemide-Low Intensification, Q12 hour bolus arm of the DOSE trial))~* Symptoms of congestion and clinical evidence at the time of final screening for eligibility:~* Fluid overload manifested by at least 2 of the following:~  1. Pitting edema ≥2+ of the lower extremities~ 2. Jugular venous pressure \>8 cm H2O~ 3. Pulmonary congestion or pleural effusion on chest x-ray~ 4. Paroxysmal nocturnal dyspnea or ≥2- pillow orthopnea~ 5. Respiration rate ≥20 per minute~* Additional objective documentation of congestion: Lung or inferior vena cava ultrasound, chest x-ray or elevated filling pressures, if available, at the time of randomization (optional)~Exclusion Criteria:~General:~* Any condition which could interfere with the patient's ability to comply with the study~* In case of female patients, pregnancy or lactation period~* Participation in an interventional clinical study during the preceding 30 days~* Previous participation in the same study~* Unwillingness or inability to complete follow up~* Active drug or alcohol abuse (smoking allowed)~Study-specific:~* Acute coronary syndrome requiring intervention during index hospitalization~* Severe renal dysfunction requiring renal replacement therapy~* Systolic blood pressure \< 90 mmHg at the time of randomization~* Pulmonary hypertension not secondary to left heart disease~* Pulmonary disease thought to be primarily responsible for symptoms~* Contraindication to systemic anticoagulation~* Severe concomitant disease expected to prolong hospitalization or to cause death in ≤ 90 days~* Sepsis~* Severe uncorrected valvular stenosis at the time of randomization~* Active myocarditis~* Hypertrophic obstructive cardiomyopathy~* Constrictive pericarditis or restrictive cardiomyopathy~* Liver cirrhosis due to primary liver disease\* (\*Restriction due to primary liver disease was present after amendment in study protocol version 5.0 but not in version 3.0)~* Known infection with human immunodeficiency virus (HIV) or active hepatitis C~* Previous solid organ transplant~* Presence or requirement for mechanical respiratory support~* Presence or requirement of a mechanical circulatory support device~* Need for IV positive inotropic agents at the time of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrafiltration Group (Type: ACTIVE_COMPARATOR): Veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm.
- Control group (Usual care IV diuretics) (Type: OTHER): Guideline-directed therapy including IV loop diuretics according to treatment algorithm.

Based on this trial design, predict the completion outcome and termination type (if applicable).